Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 1.531
Filtrer
1.
Support Care Cancer ; 32(8): 534, 2024 Jul 22.
Article de Anglais | MEDLINE | ID: mdl-39037597

RÉSUMÉ

OBJECTIVE: Prostate cancer hormonal treatments (e.g. androgen deprivation therapy) yield clinical benefits. However, there is increasing evidence these treatments may adversely impact cognitive functioning. This study aimed to qualitatively characterise the nature and impact of cognitive difficulties following these treatments. METHODS: Prostate cancer survivors (PCS) self-reporting cognitive difficulties following hormonal treatments (via an online survey) and their partners were invited to participate in semi-structured interviews. Telephone or videoconferencing interviews were conducted, then transcribed, double-coded and analysed using the Framework Method, following the principles of Interpretative Phenomenological Analysis. RESULTS: Eleven participants (six PCS and five partners) were interviewed. PCS reported a range of cognitive difficulties, verified by their partners, including forgetfulness, "fogginess", fatigue and slowed processing speed. For some PCS, word-finding difficulties, tangential speech and memory problems were apparent during interviews. The aetiology of the reported cognitive difficulties was unclear as it was attributed to a possible combination of cancer treatments, compounding side-effects (e.g. fatigue, sleep problems, hot flashes), exacerbation of pre-existing conditions and/or age-related changes. Cognitive difficulties were reported to have led to shifts in self-perception, interpersonal dynamics and increased emotionality. Engagement in cognitively-stimulating activities and reliance on compensatory strategies were reported to be helpful in managing some cognitive difficulties. All participants endorsed the potential benefits of neuropsychological intervention. CONCLUSIONS: There are a diverse range of cognitive difficulties following hormonal treatments for prostate cancer experienced by PCS and their partners. Understanding the impact of these difficulties is important for the development of targeted neuropsychological interventions.


Sujet(s)
Antagonistes des androgènes , Survivants du cancer , Tumeurs de la prostate , Humains , Mâle , Tumeurs de la prostate/traitement médicamenteux , Tumeurs de la prostate/psychologie , Sujet âgé , Adulte d'âge moyen , Antagonistes des androgènes/effets indésirables , Survivants du cancer/psychologie , Antinéoplasiques hormonaux/effets indésirables , Dysfonctionnement cognitif/étiologie , Dysfonctionnement cognitif/induit chimiquement , Recherche qualitative , Entretiens comme sujet , Femelle , Enquêtes et questionnaires
2.
Sci Rep ; 14(1): 14205, 2024 06 20.
Article de Anglais | MEDLINE | ID: mdl-38902507

RÉSUMÉ

Acetaminophen (APAP) is a leading cause of acute liver failure. The effect of APAP metabolite's effects in the periphery are well characterized; however, associated consequences in the brain remain poorly understood. Animal studies on this subject are few and reveal that frequent APAP intake can trigger cerebral abnormalities that vary depending on the subject's age. Alarmingly, experimental efforts have yet to examine associated consequences in elderly hosts, who correspond to the highest risk of medication overload, impaired drug clearance, and cognitive deficits. Here, we interrogated the cerebral and peripheral pathology of elderly mice submitted to monthly episodes of APAP intoxication since a young adult age. We found that weeks after the final episode of recurrent APAP exposure, mice exhibited worsened non-spatial memory deficit whereas spatial memory performance was unaltered. Interestingly, one month after the period of APAP intoxication, these mice showed increased glial burden without associated drivers, namely, blood-brain barrier disruption, cholesterol accumulation, and elevation of inflammatory molecules in the brain and/or periphery. Our experimental study reveals how recurrent APAP exposure affects the cognitive performance and cellular events in elderly brains. These data suggest that APAP-containing pharmacological interventions may foreshadow the elevated risk of neuropsychiatric disorders that afflict elderly populations.


Sujet(s)
Acétaminophène , Astrocytes , Dysfonctionnement cognitif , Microglie , Animaux , Acétaminophène/toxicité , Acétaminophène/effets indésirables , Dysfonctionnement cognitif/induit chimiquement , Dysfonctionnement cognitif/anatomopathologie , Dysfonctionnement cognitif/métabolisme , Souris , Astrocytes/métabolisme , Astrocytes/effets des médicaments et des substances chimiques , Astrocytes/anatomopathologie , Microglie/métabolisme , Microglie/effets des médicaments et des substances chimiques , Microglie/anatomopathologie , Mâle , Encéphale/métabolisme , Encéphale/effets des médicaments et des substances chimiques , Encéphale/anatomopathologie , Souris de lignée C57BL , Barrière hémato-encéphalique/métabolisme , Barrière hémato-encéphalique/effets des médicaments et des substances chimiques , Vieillissement , Modèles animaux de maladie humaine , Mémoire spatiale/effets des médicaments et des substances chimiques
3.
Sci Adv ; 10(25): eadn8709, 2024 Jun 21.
Article de Anglais | MEDLINE | ID: mdl-38905345

RÉSUMÉ

Androgen deprivation therapy (ADT) for prostate cancer is associated with an increased risk of dementia, including Alzheimer's disease (AD). The mechanistic connection between ADT and AD-related cognitive impairment in patients with prostate cancer remains elusive. We established a clinically relevant prostate cancer-bearing AD mouse model to explore this. Both tumor-bearing and ADT induce complex changes in immune and inflammatory responses in peripheral blood and in the brain. ADT disrupts the integrity of the blood-brain barrier (BBB) and promotes immune cell infiltration into the brain, enhancing neuroinflammation and gliosis without affecting the amyloid plaque load. Moreover, treatment with natalizumab, an FDA-approved drug targeting peripheral immune cell infiltration, reduces neuroinflammation and improves cognitive function in this model. Our study uncovers an inflammatory mechanism, extending beyond amyloid pathology, that underlies ADT-exacerbated cognitive deficits, and suggests natalizumab as a potentially effective treatment in alleviating the detrimental effects of ADT on cognition.


Sujet(s)
Maladie d'Alzheimer , Antagonistes des androgènes , Barrière hémato-encéphalique , Encéphale , Dysfonctionnement cognitif , Modèles animaux de maladie humaine , Animaux , Maladie d'Alzheimer/traitement médicamenteux , Maladie d'Alzheimer/anatomopathologie , Maladie d'Alzheimer/métabolisme , Mâle , Dysfonctionnement cognitif/traitement médicamenteux , Dysfonctionnement cognitif/induit chimiquement , Dysfonctionnement cognitif/anatomopathologie , Dysfonctionnement cognitif/étiologie , Souris , Encéphale/effets des médicaments et des substances chimiques , Encéphale/anatomopathologie , Encéphale/métabolisme , Humains , Barrière hémato-encéphalique/effets des médicaments et des substances chimiques , Barrière hémato-encéphalique/métabolisme , Antagonistes des androgènes/effets indésirables , Antagonistes des androgènes/pharmacologie , Tumeurs de la prostate/traitement médicamenteux , Tumeurs de la prostate/anatomopathologie , Natalizumab/effets indésirables , Natalizumab/pharmacologie , Natalizumab/usage thérapeutique , Plaque amyloïde/anatomopathologie , Plaque amyloïde/traitement médicamenteux
4.
BMC Anesthesiol ; 24(1): 200, 2024 Jun 05.
Article de Anglais | MEDLINE | ID: mdl-38840092

RÉSUMÉ

BACKGROUND: The inhalational anesthetic isoflurane is commonly utilized in clinical practice, particularly in the field of pediatric anesthesia. Research has demonstrated its capacity to induce neuroinflammation and long-term behavioral disorders; however, the underlying mechanism remains unclear [1]. The cation-chloride cotransporters Na+-K+-2Cl--1 (NKCC1) and K+-2Cl--2 (KCC2) play a pivotal role in regulating neuronal responses to gamma-aminobutyric acid (GABA) [2]. Imbalances in NKCC1/KCC2 can disrupt GABA neurotransmission, potentially leading to neural circuit hyperexcitability and reduced inhibition following neonatal exposure to anesthesia [3]. Therefore, this study postulates that anesthetics have the potential to dysregulate NKCC1 and/or KCC2 during brain development. METHODS: We administered 1.5% isoflurane anesthesia to neonatal rats for a duration of 4 h at postnatal day 7 (PND7). Anxiety levels were assessed using the open field test at PND28, while cognitive function was evaluated using the Morris water maze test between PND31 and PND34. Protein levels of NKCC1, KCC2, BDNF, and phosphorylated ERK (P-ERK) in the hippocampus were measured through Western blotting analysis. Pro-inflammatory cytokines IL-1ß, IL-6, and TNF-α were quantified using ELISA. RESULTS: We observed a decrease in locomotion trajectories within the central region and a significantly shorter total distance in the ISO group compared to CON pups, indicating that isoflurane induces anxiety-like behavior. In the Morris water maze (MWM) test, rats exposed to isoflurane exhibited prolonged escape latency onto the platform. Additionally, isoflurane administration resulted in reduced time spent crossing in the MWM experiment at PND34, suggesting long-term impairment of memory function. Furthermore, we found that isoflurane triggered activation of pro-inflammatory cytokines IL-1ß, IL-6, and TNF-α; downregulated KCC2/BDNF/P-ERK expression; and increased the NKCC1/KCC2 ratio in the hippocampus of PND7 rats. Bumetadine (NKCC1 specific inhibitors) reversed cognitive damage and effective disorder induced by isoflurane in neonatal rats by inhibiting TNF-α activation, normalizing IL-6 and IL-1ß levels, restoring KCC2 expression levels as well as BDNF and ERK signaling pathways. Based on these findings, it can be speculated that BDNF, P-ERK, IL-1ß, IL-6 and TNF - α may act downstream of the NKCC1/KCC2 pathway. CONCLUSIONS: Our findings provide evidence that isoflurane administration in neonatal rats leads to persistent cognitive deficits through dysregulation of the Cation-Chloride Cotransporters NKCC1 and KCC2, BDNF, p-ERK proteins, as well as neuroinflammatory processes.


Sujet(s)
Anesthésiques par inhalation , Animaux nouveau-nés , Isoflurane , , Membre-2 de la famille-12 des transporteurs de solutés , Symporteurs , Animaux , Isoflurane/pharmacologie , Membre-2 de la famille-12 des transporteurs de solutés/métabolisme , Symporteurs/métabolisme , Anesthésiques par inhalation/pharmacologie , Anesthésiques par inhalation/effets indésirables , Rats , Souris , Rat Sprague-Dawley , Mâle , Maladies neuro-inflammatoires/induit chimiquement , Maladies neuro-inflammatoires/métabolisme , Femelle , Dysfonctionnement cognitif/induit chimiquement , Dysfonctionnement cognitif/métabolisme
5.
Int J Biol Macromol ; 273(Pt 1): 133035, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38866276

RÉSUMÉ

The early symptoms of neurodegenerative diseases include oxidative stress disorder and accelerated inflammation levels. Edible fungi polysaccharides play essential roles in anti-neuroinflammation. We analyzed the regulatory mechanisms of polysaccharides from extracellular Armillariella tabescens (ATEP) in alleviating neuroinflammation in mice. Mice were induced with d-galactose and aluminum chloride to establish an animal model of Alzheimer's disease, then intragastrically treated with ATEP, which had been previously analyzed for its physicochemical properties. We assessed the critical characteristics of mice treated for neuroinflammation, including cognitive behavior, the anti-inflammatory potential of ATEP in hippocampal pathology and critical protein expression, and changes in fecal microbial composition and metabolites. ATEP intervened in oxidative stress by enhancing antioxidant enzyme activities and suppressing the Keap-1/Nrf2 signaling pathway. Changing the Nrf2 content in the nucleus led to changes in the downstream oxidation-related enzymes, HO-1, NQO-1, iNOS, and COX-2, and the neuronal morphology in CA3 region of the hippocampus. Microbiome analysis revealed that ATEP remodeled the gut microbiotas and regulated the short-chain fatty acids-producing bacteria. Early intervention with ATEP via active dietary supplementation may promote neuroprotection.


Sujet(s)
Protéine-1 de type kelch associée à ECH , Facteur-2 apparenté à NF-E2 , Stress oxydatif , Polyosides , Transduction du signal , Animaux , Facteur-2 apparenté à NF-E2/métabolisme , Souris , Transduction du signal/effets des médicaments et des substances chimiques , Protéine-1 de type kelch associée à ECH/métabolisme , Polyosides/pharmacologie , Polyosides/composition chimique , Stress oxydatif/effets des médicaments et des substances chimiques , Mâle , Maladies neuro-inflammatoires/métabolisme , Maladies neuro-inflammatoires/traitement médicamenteux , Hippocampe/métabolisme , Hippocampe/effets des médicaments et des substances chimiques , Galactose , Dysfonctionnement cognitif/traitement médicamenteux , Dysfonctionnement cognitif/métabolisme , Dysfonctionnement cognitif/induit chimiquement , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Polysaccharides fongiques/pharmacologie , Polysaccharides fongiques/composition chimique , Maladie d'Alzheimer/traitement médicamenteux , Maladie d'Alzheimer/métabolisme , Maladie d'Alzheimer/induit chimiquement
6.
Sci Total Environ ; 946: 174202, 2024 Oct 10.
Article de Anglais | MEDLINE | ID: mdl-38925396

RÉSUMÉ

Coal dust (CD) is a common pollutant, and epidemiological surveys indicate that long-term exposure to coal dust not only leads to the occurrence of pulmonary diseases but also has certain impacts on cognitive abilities. However, there is little open-published literature on the effects and specific mechanisms of coal dust exposure on the cognition of patients with Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD). An animal model has been built in this study with clinical population samples to explore the changes in neuroinflammation and cognitive abilities with coal dust exposure. In the animal model, compared to C57BL/6 mice, APP/PS1 mice exposed to coal dust exhibited more severe cognitive impairment, accompanied by significantly elevated levels of neuroinflammatory factors Apolipoprotein E4 (AOPE4) and Interleukin-6 (IL6) in the hippocampus, and more severe neuronal damage. In clinical sample sequencing, it was found that there is significant upregulation of AOPE4, neutrophils, and IL6 expression in the peripheral blood of MCI patients compared to normal individuals. Mechanistically, cell experiments revealed that IL6 could promote the phosphorylation of ERK1/2 and enhance the expression of transcription factor SP1, thereby promoting AOPE4 expression. The results of this study suggest that coal dust can promote the upregulation of IL6 and AOPE4 in patients, exacerbating cognitive impairment.


Sujet(s)
Charbon , Dysfonctionnement cognitif , Poussière , Interleukine-6 , Souris de lignée C57BL , Dysfonctionnement cognitif/induit chimiquement , Animaux , Souris , Interleukine-6/métabolisme , Système de signalisation des MAP kinases , Facteur de transcription Sp1/métabolisme , Humains , Transduction du signal , Maladie d'Alzheimer , Mâle
7.
Food Funct ; 15(13): 7063-7080, 2024 Jul 01.
Article de Anglais | MEDLINE | ID: mdl-38867661

RÉSUMÉ

Diet adjustment will affect the health of gut microbiota, which in turn influences the development and function of the organism's brain through the gut-brain axis. Walnut oil (WO), peony seed oil (PSO) and camellia seed oil (CSO), as typical representatives of woody plant oils, have been shown to have the potential to improve cognitive impairment in mice, but the function mechanisms are not clear. In this study, we comparatively investigated the neuroprotective effects of these three oils on D-galactose (D-gal)-induced cognitive impairment in mice, and found that the ameliorative effect of WO was more prominent. During the behavioral experiments, supplementation with all three oils would improve spatial learning and memory functions in D-gal mice, with a significant reduction in the error times (p < 0.001) and a significant increase in step-down latency (p < 0.001); walnut oil supplementation also significantly increased the number of hidden platform traversals, the target quadrant spent times and percentage of distance (p < 0.05). The results of biomarker analysis showed that WO, in addition to significantly inhibiting D-gal-induced oxidative stress and neuroinflammation as did PSO, significantly increased the ACh content in the mouse brain (p < 0.05) and modulated neurotransmitter levels. The results of further microbiota diversity sequencing experiments also confirmed that dietary supplementation with all three oils affected the diversity and composition of the gut microbiota in mice. Among them, WO significantly restored the balance of the mouse gut microbiota by increasing the abundance of beneficial bacteria (Bacteroidetes, Actinobacteria, Firmicutes) and decreasing the abundance of harmful bacteria (Clostridium, Shigella, Serratia), which was consistent with the results of behavioral experiments and biomarker analyses. Based on the analysis of the fatty acid composition of the three oils and changes in the gut microbiota, it is hypothesized that there is a correlation between the fatty acid composition of the dietary supplement oils and neuroprotective effects. The superiority of WO over PSO and CSO in improving cognitive impairment is mainly attributed to its balanced composition of omega-6 and omega-3 fatty acids.


Sujet(s)
Camellia , Dysfonctionnement cognitif , Galactose , Microbiome gastro-intestinal , Juglans , Huiles végétales , Graines , Animaux , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Souris , Camellia/composition chimique , Juglans/composition chimique , Huiles végétales/pharmacologie , Galactose/effets indésirables , Dysfonctionnement cognitif/traitement médicamenteux , Dysfonctionnement cognitif/induit chimiquement , Mâle , Graines/composition chimique , Bactéries/classification , Bactéries/effets des médicaments et des substances chimiques , Encéphale/effets des médicaments et des substances chimiques , Encéphale/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques
8.
Brain Behav ; 14(7): e3610, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38945806

RÉSUMÉ

INTRODUCTION: Pregnant women may need to undergo non-obstetric surgery under general anesthesia owing to medical needs, and pregnant women frequently experience sleep disturbances during late gestation. Preclinical studies demonstrated that maternal isoflurane exposure (MISO) or maternal sleep deprivation (MSD) contributed to cognitive impairments in offspring. Research studies in mice have revealed that SD can aggravate isoflurane-induced cognitive deficits. However, it remains unclear whether MSD aggravates MISO-induced cognitive deficits in offspring. The purpose of this research was to explore the combined effects of MSD and MISO on offspring cognitive function and the role of neuroinflammation and synaptic function in the process of MSD + MISO. METHODS: Pregnant mice were exposed to 1.4% isoflurane by inhalation for 4 h on gestational day (GD) 14. Dams were then subjected to SD for 6 h (12:00-18:00 h) during GD15-21. At 3 months of age, the offspring mice were subjected to the Morris water maze test to assess cognitive function. Then the levels of inflammatory and anti-inflammatory markers and synaptic function-related proteins were assessed using molecular biology methods. RESULTS: The results of this study demonstrated that MISO led to cognitive dysfunction, an effect that was aggravated by MSD. In addition, MSD exacerbated the maternal isoflurane inhalation, leading to an enhancement in the expression levels of interleukin (IL)-1ß, IL-6, and tumor necrosis factor-alpha and a reduction in the hippocampal levels of IL-10, synaptophysin, post-synaptic density-95, growth-associated protein-43, and brain-derived neurotrophic factor. CONCLUSION: Our findings revealed that MSD aggravated the cognitive deficits induced by MISO in male offspring mice, and these results were associated with neuroinflammation and alternations in synaptic function.


Sujet(s)
Anesthésiques par inhalation , Dysfonctionnement cognitif , Hippocampe , Isoflurane , Maladies neuro-inflammatoires , Effets différés de l'exposition prénatale à des facteurs de risque , Privation de sommeil , Animaux , Isoflurane/effets indésirables , Isoflurane/pharmacologie , Isoflurane/administration et posologie , Femelle , Dysfonctionnement cognitif/étiologie , Dysfonctionnement cognitif/induit chimiquement , Dysfonctionnement cognitif/physiopathologie , Grossesse , Privation de sommeil/complications , Privation de sommeil/physiopathologie , Souris , Hippocampe/métabolisme , Hippocampe/effets des médicaments et des substances chimiques , Effets différés de l'exposition prénatale à des facteurs de risque/physiopathologie , Anesthésiques par inhalation/effets indésirables , Anesthésiques par inhalation/pharmacologie , Anesthésiques par inhalation/administration et posologie , Synapses/effets des médicaments et des substances chimiques , Mâle , Souris de lignée C57BL , Séparation d'avec la mère , Facteur neurotrophique dérivé du cerveau/métabolisme
9.
J Parkinsons Dis ; 14(4): 737-746, 2024.
Article de Anglais | MEDLINE | ID: mdl-38820021

RÉSUMÉ

Background: The penetrance of common genetic risk variants for Parkinson's disease (PD) is low. Pesticide exposure increases PD risk, but how exposure affects penetrance is not well understood. Objective: To determine the relationship between occupational pesticide exposure and PD in people with LRRK2 and GBA risk variants. Methods: Participants of the Parkinson's Progression Markers Initiative (PPMI) with a LRRK2-G2019 S or GBA risk variant provided information about occupational pesticide exposure. We compared exposure in carriers with and without PD. Among carriers with PD, we used Cox proportional hazard models to compare time-to impairment in balance, cognition, and activities of daily living (ADLs) between participants with and without prior occupational pesticide exposure. Results: 378 participants with a risk variant provided exposure information; 176 with LRRK2-G2019 S (54 with and 122 without PD) and 202 with GBA variants (47 with and 155 without PD). Twenty-six participants reported pesticide exposure. People with a GBA variant and occupational pesticide exposure had much higher odds of PD (aOR: 5.4, 95% CI 1.7-18.5, p < 0.01). People with a LRRK2 variant and a history of occupational pesticide exposure had non-significantly elevated odds of PD (aOR 1.3, 95% CI 0.4-4.6, p = 0.7). Among those with PD, pesticide exposure was associated with a higher risk of balance problems and cognitive impairment in LRRK2-PD and functional impairment in GBA-PD, although associations were not statistically significant. Conclusions: Occupational pesticide exposure may increase penetrance of GBA-PD and may be associated with faster symptom progression. Further studies in larger cohorts are necessary.


Sujet(s)
Glucosylceramidase , Leucine-rich repeat serine-threonine protein kinase-2 , Exposition professionnelle , Maladie de Parkinson , Pesticides , Humains , Leucine-rich repeat serine-threonine protein kinase-2/génétique , Femelle , Maladie de Parkinson/génétique , Mâle , Glucosylceramidase/génétique , Exposition professionnelle/effets indésirables , Pesticides/effets indésirables , Sujet âgé , Adulte d'âge moyen , Pénétrance , Activités de la vie quotidienne , Dysfonctionnement cognitif/étiologie , Dysfonctionnement cognitif/génétique , Dysfonctionnement cognitif/induit chimiquement
10.
Neurotox Res ; 42(3): 27, 2024 May 31.
Article de Anglais | MEDLINE | ID: mdl-38819761

RÉSUMÉ

Early and prolonged exposure to anesthetic agents could cause neurodevelopmental disorders in children. Astrocytes, heavily outnumber neurons in the brain, are crucial regulators of synaptic formation and function during development. However, how general anesthetics act on astrocytes and the impact on cognition are still unclear. In this study, we investigated the role of ferroptosis and GPX4, a major hydroperoxide scavenger playing a pivotal role in suppressing the process of ferroptosis, and their underlying mechanism in isoflurane-induced cytotoxicity in astrocytes and cognitive impairment. Our results showed that early 6 h isoflurane anesthesia induced cognitive impairment in mice. Ferroptosis-relative genes and metabolic changes were involved in the pathological process of isoflurane-induced cytotoxicity in astrocytes. The level of GPX4 was decreased while the expression of 4-HNE and generation of ROS were elevated after isoflurane exposure. Selectively blocking ferroptosis with Fer-1 attenuated the abovementioned cytotoxicity in astrocytes, paralleling with the reverse of the changes in GPX4, ROS and 4-HNE secondary to isoflurane anesthesia. Fer-1 attenuated the cognitive impairment induced by prolonged isoflurane exposure. Thus, ferroptosis conduced towards isoflurane-induced cytotoxicity in astrocytes via suppressing GPX4 and promoting lipid peroxidation. Fer-1 was expected to be an underlying intervention for the neurotoxicity induced by isoflurane in the developing brain, and to alleviate cognitive impairment in neonates.


Sujet(s)
Animaux nouveau-nés , Astrocytes , Dysfonctionnement cognitif , Ferroptose , Isoflurane , Animaux , Astrocytes/effets des médicaments et des substances chimiques , Astrocytes/métabolisme , Isoflurane/toxicité , Ferroptose/effets des médicaments et des substances chimiques , Ferroptose/physiologie , Dysfonctionnement cognitif/induit chimiquement , Dysfonctionnement cognitif/prévention et contrôle , Dysfonctionnement cognitif/métabolisme , Souris , Anesthésiques par inhalation/toxicité , Souris de lignée C57BL , Neuroprotecteurs/pharmacologie , Phospholipid hydroperoxide glutathione peroxidase/métabolisme , Espèces réactives de l'oxygène/métabolisme
11.
Behav Brain Res ; 469: 115006, 2024 Jul 09.
Article de Anglais | MEDLINE | ID: mdl-38692357

RÉSUMÉ

The nuclear factor erythroid 2-related factor 2 (Nrf2) signalling pathway represents a crucial intrinsic protective system against oxidative stress and inflammation and plays a significant role in various neurological disorders. However, the effect of Nrf2 signalling on the regulation of cognitive impairment remains unknown. Dexmedetomidine (DEX) has neuroprotective effects and can ameliorate lipopolysaccharide (LPS)-induced cognitive dysfunction. Our objective was to observe whether Nrf2 knockout influences the efficacy of DEX in improving cognitive impairment and to attempt to understand its underlying mechanisms. An LPS-induced cognitive dysfunction model in wild-type and Nrf2 knockout mice (Institute of Cancer Research background; male; 8-12 weeks) was used to observe the impact of DEX on cognitive dysfunction. LPS was intraperitoneally injected, followed by novel object recognition and morris water maze experiments 24 h later. Hippocampal tissues were collected for histopathological and molecular analyses. Our research findings suggest that DEX enhances the expression of NQO1, HO-1, PSD95, and SYP proteins in hippocampal tissue, inhibits microglial proliferation, reduces pro-inflammatory cytokines IL-1ß and TNF-ɑ, increases anti-inflammatory cytokine IL-10, and improves dendritic spine density, thereby alleviating cognitive dysfunction induced by LPS. However, the knockout of the Nrf2 gene negated the aforementioned effects of DEX. In conclusion, DEX alleviates cognitive deficits induced by LPS through mechanisms of anti-oxidative stress and anti-inflammation, as well as by increasing synaptic protein expression and dendritic spine density. However, the knockout of the Nrf2 gene reversed the effects of DEX. The Nrf2 signaling pathway plays a crucial role in the mitigation of LPS-induced cognitive impairment by DEX.


Sujet(s)
Dysfonctionnement cognitif , Dexmédétomidine , Modèles animaux de maladie humaine , Hippocampe , Lipopolysaccharides , Souris knockout , Facteur-2 apparenté à NF-E2 , Neuroprotecteurs , Animaux , Facteur-2 apparenté à NF-E2/métabolisme , Dexmédétomidine/pharmacologie , Dysfonctionnement cognitif/traitement médicamenteux , Dysfonctionnement cognitif/métabolisme , Dysfonctionnement cognitif/induit chimiquement , Neuroprotecteurs/pharmacologie , Neuroprotecteurs/administration et posologie , Souris , Mâle , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Lipopolysaccharides/pharmacologie , Stress oxydatif/effets des médicaments et des substances chimiques , Souris de lignée C57BL , Microglie/effets des médicaments et des substances chimiques , Microglie/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques
12.
J Hazard Mater ; 474: 134756, 2024 Aug 05.
Article de Anglais | MEDLINE | ID: mdl-38820747

RÉSUMÉ

The fetus and infants are particularly vulnerable to Cadmium (Cd) due to the immaturity of the blood-brain barrier. In utero and early life exposure to Cd is associated with cognitive deficits. Although such exposure has attracted widespread attention, its gender-specificity remains controversial, and there are no reports disclosing the underlying mechanism of gender­specific neurotoxicity. We extensively evaluated the learning and cognitive functions and synaptic plasticity of male and female rats exposed to maternal Cd. Maternal Cd exposure induced learning and memory deficits in male offspring rats, but not in female offspring rats. PLCß4 was identified as a critical protein, which might be related to the gender­specific cognitive deficits in male rats. The up-regulated PLCß4 competed with PLCγ1 to bind to PIP2, which counteracted the hydrolysis of PIP2 by PLCγ1. The decreased activation of PLCγ1 inhibited the phosphorylation of CREB to reduce BDNF transcription, which consequently resulted in the damage of hippocampal neurons and cognitive deficiency. Moreover, the low level of BDNF promoted AEP activation to induce Aß deposition in the hippocampus. These findings highlight that PLCß4 might be a potential target for the therapy of learning and cognitive deficits caused by Cd exposure in early life.


Sujet(s)
Facteur neurotrophique dérivé du cerveau , Cadmium , Dysfonctionnement cognitif , Protéine de liaison à l'élément de réponse à l'AMP cyclique , Hippocampe , Lactation , Phospholipase C gamma , Effets différés de l'exposition prénatale à des facteurs de risque , Transduction du signal , Animaux , Femelle , Mâle , Grossesse , Cadmium/toxicité , Facteur neurotrophique dérivé du cerveau/métabolisme , Phospholipase C gamma/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Protéine de liaison à l'élément de réponse à l'AMP cyclique/métabolisme , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Dysfonctionnement cognitif/induit chimiquement , Phospholipase C beta/métabolisme , Rat Sprague-Dawley , Phosphatidylinositol diphosphate-4,5/métabolisme , Exposition maternelle , Rats
13.
J Integr Neurosci ; 23(5): 107, 2024 May 24.
Article de Anglais | MEDLINE | ID: mdl-38812388

RÉSUMÉ

BACKGROUND: Methamphetamine (METH) is a highly addictive drug that directly affects the central nervous system. METH use not only harms the user's health but also poses risks and costs to society. Prolonged METH dependence has been shown to impair cognition, which may be the primary factor in impulsive drug-seeking behaviors and high relapse rates. However, the molecular mechanisms underlying METH addiction and METH-induced cognitive decline remain poorly understood. METHODS: To illuminate the potential molecular mechanisms underpinning METH addiction, we compared serum protein expression levels between 12 long-term METH users and 12 healthy controls using label-free quantitative proteomics. Bioinformatic analyses were conducted to determine functional networks and protein-protein interactions. RESULTS: In total, 23 differentially expressed proteins were identified between the two groups. The differentially expressed proteins were related to cognitive dysfunction, neuroinflammation, immune impairment, metabolic disturbances, and calcium binding and regulation. CONCLUSIONS: These 23 proteins may underpin the multi-system damage induced by chronic METH exposure. Our findings provide novel insights into the molecular basis of METH addiction and inform potential prevention and treatment strategies for individuals with METH dependence.


Sujet(s)
Troubles liés aux amphétamines , Stimulants du système nerveux central , Dysfonctionnement cognitif , Métamfétamine , Protéomique , Humains , Troubles liés aux amphétamines/métabolisme , Mâle , Métamfétamine/effets indésirables , Dysfonctionnement cognitif/métabolisme , Dysfonctionnement cognitif/induit chimiquement , Dysfonctionnement cognitif/étiologie , Adulte , Stimulants du système nerveux central/effets indésirables , Stimulants du système nerveux central/pharmacologie , Femelle , Jeune adulte
14.
J Neuroimmune Pharmacol ; 19(1): 24, 2024 May 23.
Article de Anglais | MEDLINE | ID: mdl-38780885

RÉSUMÉ

Cornuside has been discovered to improve learning and memory in AD mice, however, its underlying mechanism was not fully understood. In the present study, we established an AD mice model by intracerebroventricular injection of Aß1-42, which were treated with cornuside (3, 10, 30 mg/kg) for 2 weeks. Cornuside significantly ameliorated cognitive function of AD mice in series of behavioral tests, including Morris water maze test, nest building test, novel object recognition test and step-down test. Additionally, cornuside could attenuate neuronal injury, and promote cholinergic synaptic transmission by restoring the level of acetylcholine (ACh) via inhibiting acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as facilitating choline acetyltransferase (ChAT). Furthermore, cornuside inhibited oxidative stress levels amplified as decreased malondialdehyde (MDA), by inhibiting TXNIP expression, improving total anti-oxidative capacity (TAOC), raising activities of superoxide dismutase (SOD) and catalase (CAT). Cornuside also reduced the activation of microglia and astrocytes, decreased the level of proinflammatory factors TNF-α, IL-6, IL-1ß, iNOS and COX2 via interfering RAGE-mediated IKK-IκB-NF-κB phosphorylation. Similar anti-oxidative and anti-inflammatory effects were also found in LPS-stimulated BV2 cells via hampering RAGE-mediated TXNIP activation and NF-κB nuclear translocation. Virtual docking revealed that cornuside could interact with the active pocket of RAGE V domain directly. In conclusion, cornuside could bind to the RAGE directly impeding the interaction of Aß and RAGE, and cut down the expression of TXNIP inhibiting ROS production and oxidative stress, as well as hamper NF-κB p65 mediated the inflammation.


Sujet(s)
Maladie d'Alzheimer , Peptides bêta-amyloïdes , Dysfonctionnement cognitif , Facteur de transcription NF-kappa B , Fragments peptidiques , Récepteur spécifique des produits finaux de glycosylation avancée , Transduction du signal , Animaux , Souris , Maladie d'Alzheimer/traitement médicamenteux , Maladie d'Alzheimer/métabolisme , Maladie d'Alzheimer/induit chimiquement , Peptides bêta-amyloïdes/toxicité , Peptides bêta-amyloïdes/métabolisme , Fragments peptidiques/toxicité , Dysfonctionnement cognitif/traitement médicamenteux , Dysfonctionnement cognitif/métabolisme , Dysfonctionnement cognitif/induit chimiquement , Transduction du signal/effets des médicaments et des substances chimiques , Récepteur spécifique des produits finaux de glycosylation avancée/métabolisme , Facteur de transcription NF-kappa B/métabolisme , Mâle , Stress oxydatif/effets des médicaments et des substances chimiques
15.
Braz J Med Biol Res ; 57: e13437, 2024.
Article de Anglais | MEDLINE | ID: mdl-38808889

RÉSUMÉ

Clinical studies have found that neonatal sevoflurane exposure can increase the risk of cognitive dysfunction. However, recent studies have found that it can exhibit neuroprotective effects in some situations. In this study, we aimed to explore the effects of sevoflurane neonatal exposure in rats. A total of 144 rat pups (72 males and 72 females) were assigned to six groups and separately according to sevoflurane exposure of different times on the seventh day after birth. Blood gas analysis and western blot detection in the hippocampus were conducted after exposure. The Morris water maze test was conducted on the 32nd to 38th days after birth. The expression of PSD95 and synaptophysin in the hippocampus was detected after the Morris water maze test. We found that neonatal exposure to sevoflurane promoted apoptosis in the hippocampus, and Bax and caspase-3 were increased in a dose-dependent manner. The 2-h exposure had the greatest effects on cognitive dysfunction. However, with the extension of exposure time to 6 h, the effects on cognitive function were partly compensated. In addition, sevoflurane exposure decreased synaptogenesis in the hippocampus. However, as the exposure time was extended, the suppression of synaptogenesis was attenuated. In conclusion, neonatal sevoflurane exposure exhibited duration-dependent effects on cognitive function via Bax-caspase-3-dependent apoptosis and bidirectional effects on synaptogenesis in rats.


Sujet(s)
Animaux nouveau-nés , Cognition , Hippocampe , Sévoflurane , Sévoflurane/pharmacologie , Animaux , Femelle , Mâle , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Rats , Cognition/effets des médicaments et des substances chimiques , Facteurs temps , Apprentissage du labyrinthe/effets des médicaments et des substances chimiques , Anesthésiques par inhalation/pharmacologie , Anesthésiques par inhalation/effets indésirables , Apoptose/effets des médicaments et des substances chimiques , Facteurs sexuels , Rat Sprague-Dawley , Éthers méthyliques/pharmacologie , Technique de Western , Gazométrie sanguine , Dysfonctionnement cognitif/induit chimiquement
16.
Zh Nevrol Psikhiatr Im S S Korsakova ; 124(4. Vyp. 2): 77-85, 2024.
Article de Russe | MEDLINE | ID: mdl-38696155

RÉSUMÉ

One of the reasons for the development or worsening of cognitive impairment (CI) may be the use of a number of drugs: non-steroidal anti-inflammatory drugs, antiarrhythmics, antidepressants, glucocorticosteroids, antitumor drugs and a number of others. The negative effect of drugs on cognitive functions is realized due to many pathophysiological mechanisms: disruption of hormonal regulation, decreased neuronal excitability, increased activity of gamma-aminobutyric acid receptors, decreased cerebral circulation, atrophic changes in the brain; many mechanisms have not been fully established. Risk factors for the development of drug-induced CIs are: old age or childhood, brain damage, chronic diseases, genetic factors, the patient's initial CI, polypharmacy, dose and duration of drug use, acute infectious diseases, metabolic disorders, dehydration, acute urinary retention, etc. To diagnose and differentially diagnose drug-induced CI, it is necessary to establish a connection between the start of taking a suspected drug-inducer and a decrease in cognitive functions. The first step in the treatment of drug-induced CI is the abolition of an inducer drug or a reduction in its dose, in cases where it is impossible to discontinue the drug and there is no replacement, special slow-release dosage forms can be considered. The main measures to prevent drug-induced CI include the use of drugs with the lowest risk of their development, assessment of drug interactions, and the use of modern scales to assess the risk of developing this side-effect (anticholinergic burden scale, etc.).


Sujet(s)
Dysfonctionnement cognitif , Démence , Humains , Dysfonctionnement cognitif/induit chimiquement , Démence/induit chimiquement , Démence/traitement médicamenteux , Facteurs de risque
17.
Biomed Pharmacother ; 175: 116739, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38759288

RÉSUMÉ

BACKGROUND: Ketamine, as a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, was originally used in general anesthesia. Epidemiological data show that ketamine has become one of the most commonly abused drugs in China. Ketamine administration might cause cognitive impairment; however, its molecular mechanism remains unclear. The glymphatic system is a lymphoid system that plays a key role in metabolic waste removal and cognitive regulation in the central nervous system. METHODS: Focusing on the glymphatic system, this study evaluated the behavioral performance and circulatory function of the glymphatic system by building a short-term ketamine administration model in mice, and detected the expression levels of the 5-HT2c receptor, ΔFosb, Pten, Akt, and Aqp4 in the hippocampus. Primary astrocytes were cultured to verify the regulatory relationships among related indexes using a 5-HT2c receptor antagonist, a 5-HT2c receptor short interfering RNA (siRNA), and a ΔFosb siRNA. RESULTS: Ketamine administration induced ΔFosb accumulation by increasing 5-HT2c receptor expression in mouse hippocampal astrocytes and primary astrocytes. ΔFosb acted as a transcription factor to recognize the AATGATTAAT bases in the 5' regulatory region of the Aqp4 gene (-1096 bp to -1087 bp), which inhibited Aqp4 expression, thus causing the circulatory dysfunction of the glymphatic system, leading to cognitive impairment. CONCLUSIONS: Although this regulatory mechanism does not involve the Pten/Akt pathway, this study revealed a new mechanism of ketamine-induced cognitive impairment in non-neuronal systems, and provided a theoretical basis for the safety of clinical treatment and the effectiveness of withdrawal.


Sujet(s)
Astrocytes , Dysfonctionnement cognitif , Système glymphatique , Hippocampe , Kétamine , Animaux , Kétamine/pharmacologie , Kétamine/toxicité , Astrocytes/effets des médicaments et des substances chimiques , Astrocytes/métabolisme , Dysfonctionnement cognitif/induit chimiquement , Dysfonctionnement cognitif/métabolisme , Souris , Mâle , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Système glymphatique/effets des médicaments et des substances chimiques , Système glymphatique/métabolisme , Protéines proto-oncogènes c-akt/métabolisme , Aquaporine-4/métabolisme , Aquaporine-4/génétique , Récepteur de la sérotonine de type 5-HT2C/métabolisme , Récepteur de la sérotonine de type 5-HT2C/génétique , Souris de lignée C57BL , Cellules cultivées , Protéines proto-oncogènes c-fos/métabolisme , Protéines proto-oncogènes c-fos/génétique , Phosphohydrolase PTEN/métabolisme , Phosphohydrolase PTEN/génétique
18.
Br J Clin Pharmacol ; 90(7): 1741-1744, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38697619

RÉSUMÉ

Anticholinergic-induced cognitive impairment may be partially reversible upon cessation. A barrier to deprescribing of anticholinergics is the unknown risk of anticholinergic adverse drug withdrawal events (ADWE), with only limited information available on the incidence, timing and severity of anticholinergic ADWE. We report the case of a 76-year-old woman who experienced significant cognitive improvement following deprescribing long-term use of a strong anticholinergic drug, doxepin, and dose reduction of another possible anticholinergic agent. The patient decided to abruptly stop taking doxepin, despite a planned careful taper with twice weekly monitoring, but did not experience any severe anticholinergic ADWE and subsequently had significantly improved cognitive function. Future research should focus on better understanding the risk of anticholinergic ADWE so that anticholinergic deprescribing decisions, including how often and by how much to taper, can be made confidently and safely.


Sujet(s)
Antagonistes cholinergiques , Cognition , Déprescriptions , Humains , Femelle , Sujet âgé , Antagonistes cholinergiques/effets indésirables , Antagonistes cholinergiques/administration et posologie , Cognition/effets des médicaments et des substances chimiques , Syndrome de sevrage/traitement médicamenteux , Dysfonctionnement cognitif/induit chimiquement , Dysfonctionnement cognitif/traitement médicamenteux
19.
Neuroscience ; 549: 145-155, 2024 Jun 21.
Article de Anglais | MEDLINE | ID: mdl-38759912

RÉSUMÉ

The purpose of this study was to assess, from a behavioral, biochemical, and molecular standpoint, how exercise training affected fibromyalgia (FM) symptoms in a reserpine-induced FM model and to look into the potential involvement of the hippocampal PGC-1α/FNDC5/BDNF pathway in this process. Reserpine (1 mg kg-1) was subcutaneously injected once daily for three consecutive days and then the rats were exercised for 21 days. Mechanical allodynia was evaluated 1, 11, and 21 days after the last injection. At the end of the exercise training protocol forced swim, open field and Morris water maze tests were performed to assess depression, locomotion and cognition, respectively. Additionally, biochemical and molecular markers related to the pathogenesis of the FM and cognitive functions were measured. Reserpine exposure was associated with a decrease in locomotion, an increase in depression, an increase in mechanical allodynia, and a decrease in spatial learning and memory (p < 0.05). These behavioral abnormalities were found to be correlated with elevated blood cytokine levels, reduced serotonin levels in the prefrontal cortex, and altered PGC-1α/FNDC5/BDNF pathway in the hippocampus (p < 0.05). Interestingly, exercise training attenuated all the neuropathological changes mentioned above (p < 0.05). These results imply that exercise training restored behavioral, biochemical, and molecular changes against reserpine-induced FM-like symptoms in rats, hence mitigating the behavioral abnormalities linked to pain, depression, and cognitive functioning.


Sujet(s)
Facteur neurotrophique dérivé du cerveau , Dysfonctionnement cognitif , Modèles animaux de maladie humaine , Fibromyalgie , Hippocampe , Coactivateur 1-alpha du récepteur gamma activé par les proliférateurs de peroxysomes , Conditionnement physique d'animal , Réserpine , Animaux , Hippocampe/métabolisme , Hippocampe/effets des médicaments et des substances chimiques , Facteur neurotrophique dérivé du cerveau/métabolisme , Dysfonctionnement cognitif/induit chimiquement , Dysfonctionnement cognitif/métabolisme , Dysfonctionnement cognitif/thérapie , Conditionnement physique d'animal/physiologie , Coactivateur 1-alpha du récepteur gamma activé par les proliférateurs de peroxysomes/métabolisme , Fibromyalgie/induit chimiquement , Fibromyalgie/métabolisme , Fibromyalgie/thérapie , Rats , Transduction du signal/physiologie , Transduction du signal/effets des médicaments et des substances chimiques , Mâle , Rat Wistar , Dépression/induit chimiquement , Dépression/thérapie , Dépression/métabolisme , Hyperalgésie/métabolisme , Hyperalgésie/induit chimiquement , Hyperalgésie/thérapie , Fibronectines
20.
Neuroreport ; 35(10): 657-663, 2024 07 01.
Article de Anglais | MEDLINE | ID: mdl-38813907

RÉSUMÉ

Cisplatin-induced cognitive impairment (chemobrain) affects a considerable percentage of cancer patients and has no established pharmacological treatment. Chemobrain can be associated with neuroinflammation and oxidative stress. Melatonin, a pineal hormone, is known to have antioxidant, anti-inflammatory and neuroprotective potential. In this study, we investigated cisplatin-induced cognitive impairment in rats and whether melatonin can improve or reverse this impairment. Behavioral testing involved measuring working memory using the novel location recognition test (NLRT) under conditions of cisplatin or cisplatin + melatonin treatment, followed by the collection of rats' brains. The brains were subsequently stained with Golgi-Cox stain and then the hippocampus area CA3 of each one was examined, and dendritic spine density was calculated. Treatment with cisplatin resulted in deficits in the rats' performance in the NLRT (P < 0.05). These deficits were prevented by the coadministration of melatonin (P < 0.05). Cisplatin also reduced the density of dendritic spines in the hippocampus (P < 0.0001), specifically CA3 area, while the coadministration of melatonin significantly reversed this reduction (P < 0.001). This study showed that melatonin can ameliorate cisplatin-induced spatial memory deficits and dendritic spines density abnormalities in rats. Given that melatonin is a safe and wildly used supplement, it is feasible to explore its use as a palliative intervention in cancer treatment.


Sujet(s)
Cisplatine , Épines dendritiques , Hippocampe , Mélatonine , Animaux , Mélatonine/pharmacologie , Cisplatine/toxicité , Épines dendritiques/effets des médicaments et des substances chimiques , Épines dendritiques/anatomopathologie , Mâle , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/anatomopathologie , Hippocampe/métabolisme , Rats , Dysfonctionnement cognitif/induit chimiquement , Dysfonctionnement cognitif/prévention et contrôle , Dysfonctionnement cognitif/traitement médicamenteux , Dysfonctionnement cognitif/anatomopathologie , Antinéoplasiques/toxicité , Neuroprotecteurs/pharmacologie , Antioxydants/pharmacologie , Rat Wistar , Altération cognitive liée à la chimiothérapie , Mémoire à court terme/effets des médicaments et des substances chimiques
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE